Staging and Treatment of Dementia
|
|
|
- Lynn Mitchell
- 10 years ago
- Views:
Transcription
1 Staging and Treatment of Dementia Ami Hall DO 10/25/14 1
2 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition of Neurocognitive Disorder Evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains such as complex attention, executive function, learning, memory, language, perceptual motor or social cognition. 2
3 Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually even the ability to carry out the simplest tasks of daily living. (NIA) Vascular Dementia Vascular dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to your brain. (Mayo Clinic) 3
4 Age is the biggest risk factor Alz.org Alz.org 4
5 Not all dementia is Alzheimer s disease Jags, 1999 Case Presentation 85 y/o male Recently widowed Family visiting from out of town Spoiled food, unpaid bills, and expired medication PMH: HTN and Hyperlipidemia 5
6 Memory Test Options MMSE MOCA Mini Cog Clock drawing test Mini Cog Say three words and have the patient repeat them Clock drawing test (1 point if correct) Repeat 3 words (1 point for each recalled word) Scoring 0 2 with abnormal CDT = dementia Scoring of 1 2 with normal CDT is negative for dementia Score of 3 is negative for dementia 6
7 Clock Drawing Test Bathing Dressing Toileting Transfer Continence Feeding Katz Basic ADLs 7
8 Lawton Brody Instrumental ADLs Ability to use the telephone Shopping Food preparation Laundry Mode of transportation Responsibility for own medications Management of finances and bills Lab work and Imaging CBC, CMP, TSH, vitamin B12, (RPR) CT brain without contrast MRI (without contrast) if gait abnormality and/or tremor is present or if vascular cause is a concern 8
9 Case Presentation Bloodwork negative Imaging nondiagnostic MMSE: 18 Clock: 2 Dependent in all IADLs Able to do all his ADLs 9
10 CDR Staging CDR dementia 0 No dementia 0.5 MCI 1.0 Mild 2.0 Moderate 3.0 Severe Subjective No +/ +/ memory loss Measurable No memory loss IADLS No No Yes Yes Yes BADLs No No No Yes Yes Driving Safely Yes >50% <50% No No Medications No No ChEI ChEI and NMDA ant ChEI and NMDA ant Pharmaceutical Treatment Acetylcholinesterase Inhibitors Aricept (donepezil) Exelon (rivastigmine) Razadyne (galatamine) NMDA antagonist Namenda (memantine) 10
11 FDA Approved Therapies Mild Moderate Severe Donepezil 5-10 mg 5-10 mg 10 mg Donepezil (Aricept 23) 23 mg/d Galantamine Rivastigmine* mg/d 6(3*)-12 mg/d 4.6/9.5/13.3 patch Memantine mg/d *FDA approved for mild-moderate Parkinson s Disease related dementia 11
12 NMDA antagonist More effective when used with ACEI May help with agitation Memantine and Donepezil Combination Therapy Mean Change from Baseline Worsening Improvement Severe Impairment Battery Placebo Memantine -4.0 Baseline End Point No. of Patients Study Week (LOCF) Memantine Placebo LS Mean Difference P value < <0.001 <0.001 Mean Change from Baseline Worsening Improvement Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory Baseline End Point No. of Patients Study Week (LOCF) Memantine Placebo LS Mean Difference P value Tariot P, et al. JAMA. 2004;3:
13 Nonpharmaceutical Treatment Memory exercises ( If you don t use it, you lose it ) Physical exercise Socialization Memory Exercises Reading Puzzles Educational shows Learning a new language Learning an instrument Brain fit programs? 13
14 Exercise and cognition Meta analysis Sixteen trials with 937 participants met the inclusion criteria. Authors conclusion: exercise programs can have a significant impact in improving ADLs and cognition No effect on depression or challenging behaviors Metanalysis, Forbes, Thissen, et al, 2014 Exercise and Cognition Can a dementia specific Aquatic exercise program improve behavioral and psychological symptoms in dementia 12 week course and only 10 F and 1 M Improvement was seen in both aspects Neville and Henwood,
15 Exercise and Cognition 30 patient study comparing cognition exercises alone or cognition and physical exercise 12 week study Results showed that the group that participated in both showed improvements in both memory, balance, and quality of life Yoon, Lee 2013 OMT and Dementia Can craniosacral still point technique decrease agitation Cohen Mansfield Agitation Inventory was used to assess agitation CSPT showed a statistical reduction in M CMAI scores Gerder, Hart, and Zimmerman,
16 Music and cognition Cognitive and behavioral effects of music based exercises in patients with dementia. RCT, 15 pts exercise training for three months, which consisted of daily physical exercises supported by music for 30 min/session The present study suggests a beneficial effect of cognition using a music based exercise program in a group of patients with moderate to severe dementia. Winckel and Feys, 2004 Socialization Most social activities involve some type of cognitive process Some activities the caregiver may not have to be present for 16
17 Case Presentation CDR 1.0 (mild mixed dementia) ChEI Memory and physical exercise Social program Family assistance Follow up visits Monitor progression/confirming diagnosis Medication monitoring Monitor symptoms /adjustments in treatment Caregiver support/education Monitor for potential safety concerns 17
18 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available 18
Update on Treatment of the Dementias
Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment
Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define
Dementia: Delivering the Diagnosis
Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology University of Utah Diagnosing Dementia
The Pharmacist s Role in Recognition and Management of Alzheimer s
10:15am - 11:15am: Breakout 2 - Mental Health Option B: The Pharmacist s Role in Recognition and Management of Alzheimer s ACPE UAN 0107-0000-10-013-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based
Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
Costs of Medical Care for Dementia Patients in Taiwan: A Population-Based Study
Costs of Medical Care for Dementia Patients in Taiwan: A Population-Based Study L.-J. E. Ku 1, T.-H. Lu 1, S.-L. Wu 1, M.-C. Pai 2* 古 鯉 榕, 呂 宗 學, 吳 士 良, 白 明 奇 April 19, 2013 1 Institute of Public Health,
EMR Decision Support Tools for Alzheimer s and Related Dementias
EMR Decision Support Tools for Alzheimer s and Related Dementias 1. Screening Tool Criteria For When to Use: As a general cognitive screening tool or as part of an annual exam (Medicare Annual Wellness
Disclosures. Case: Ms. K. Case: Ms. K. Dementia: Considering When to Start, Stop, and Continue Medications 4/23/15. * Nothing to disclose
Dementia: Considering When to Start, Stop, and Continue Medications * Nothing to disclose Disclosures Lianne Hirano, MD UW Division of Gerontology & Geriatric Medicine 4/23/15 Current Concepts in Drug
Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007, August 2009) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a review of NICE
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
TABLE OF CONTENTS. 1. Introduction. 1.1. Dementia and Alzheimer Prevalence. 2. Global Alzheimer Market and Performance. 2.1.
1 Disclaimer The research reports provided by AM Mindpower Solutions are for the personal information of the authorised recipient and is not for public distribution and should not be reproduced or redistributed
Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.
Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych. Community Geriatric Mental Health Model of Continuum of Cognition with Aging Normal Mild cognitive
Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease
Understanding NICE guidance Information for people who use NHS services Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease NICE technology appraisal guidance advises on when and
Alzheimer Disease (AD)
1 Alzheimer Disease (AD) 2 Alzheimer's disease is a progressive degenerative disease that attacks the brain and results in impaired memory, thinking and behavior. It was first described by Dr. Alois Alzheimer
Dementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
Alzheimer's: The Latest Assessment and Treatment Strategies
Questions from chapter 1 Alzheimer's: The Latest Assessment and Treatment Strategies 1) What is a loss of cognitive and intellectual powers without changes in consciousness. a) dementia b) delusions c)
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease
MCDB 4777/5777 Molecular Neurobiology Lecture 38 Alzheimer s Disease Outline of Today s Lecture Why is Alzheimer s disease a problem? What is Alzheimer s Disease? What causes Alzheimer s disease? How can
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will
Guidelines for Dementia Syndrome
Guidelines for Dementia Syndrome Dementia is the chronic acquired decline in memory and at least one other cognitive function (e.g. language, visual-spatial, executive) sufficient to offset daily life.
Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease
IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect
Pharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence
Pharmacotherapy of BPSD Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Pharmacological interventions Reducing medication errors. Reducing potentially inappropriate medication prescription.
Everyone has mild memory lapses from time to time. You go
Coping With Memory Loss Everyone has mild memory lapses from time to time. You go from the kitchen to the bedroom to get something, only to find yourself wondering what you needed. You can t find your
DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE
Research DRUG APPROVAL PROCESS FOR THE TREATMENT OF ALZHEIMER S DISEASE There are certain principles that should be followed when involving people with Alzheimer s disease in research. For more information,
Emergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
NHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No:
NHS ONEL and NELFT Shared Care Guidelines Management of medications for Alzheimer s disease DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name
Memantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
Local Clinical Trials
Local Clinical Trials The Alzheimer s Association, Connecticut Chapter does not officially endorse any specific research study. The following information regarding clinical trials is provided as a service
Being an advocate for good care. Useful medications What to expect When to be concerned
Being an advocate for good care Useful medications What to expect When to be concerned Common Medical Questions 1. What medications are available to help with memory loss? Cholinesterase Inhibitors The
Diagnosis and Initial Management of Cognitive Disorders
Diagnosis and Initial Management of Cognitive Disorders January 29, 2016 Kelly Garrett, PhD Cathleen Obray, MD, MHS Neurosciences Clinical Program Cognitive Care Team None Disclosures Neurosciences Clinical
Primary Endpoints in Alzheimer s Dementia
Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in
Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease
IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl
basics of alzheimer s disease What it is and what you can do
basics of alzheimer s disease What it is and what you can do What is Alzheimer s disease? Alzheimer s (AHLZ-high-merz) is a disease of the brain that causes problems with memory, thinking and behavior.
Changing the Trajectory of Alzheimer s Disease: How a Treatment by 2025 Saves Lives and Dollars
Changing the Trajectory of Alzheimer s Disease: How a Treatment by 2025 Saves Lives and Dollars The appendices for this report including a detailed description of the model developed by The Lewin Group;
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.
U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration
Cognitive Testing for Underwriting Life Insurance
Cognitive Testing for Underwriting Life Insurance Presentation to the Mortality Working Group of the International Actuarial Association Al Klein April 8, 2011 Cognitive function Agenda What is it? What
Alzheimer s and Depression: What is the Connection?
Alzheimer s and Depression: What is the Connection? Ladson Hinton MD Professor and Director of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Director, Education Core, Alzheimer
Prediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment
Prediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment Teresa Leung Therapist Prince of Wales Hospital 7 th May, 2012 Outline of Presentation Introduction Study Objectives,
Medication for Dementia (Acetylcholinesterase Inhibitors)
Older People s Mental Health Service Medication for Dementia (Acetylcholinesterase Inhibitors) August 2011 ^ ãéãäéê çñ `~ãäêáçöé råáîéêëáíó eé~äíü m~êíåéêë What are they? A group of medications used to
Alzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
Alzheimer s Disease 2009. Alzheimer s Disease. Markets, Pipeline and Opportunities. April 2009. By John Bates Ph.D. 1 Copyright 2009 Biopharm Reports
Alzheimer s Disease Markets, Pipeline and Opportunities April 2009 By John Bates Ph.D 1 About the Author John Bates is a consultant and author in the drug markets and R&D fields. After a first degree in
Geriatric Assessment Tools. Dr. Hermes
Geriatric Assessment Tools Dr. Hermes Geriatric Assessment Learning Objectives 1. Identify factors contributing to the need for specialized assessment of the frail older adult 2. Discuss the benefits of
ASSESSMENT OF THE OLDER ADULT
ASSESSMENT OF THE OLDER ADULT OBJECTIVES Know and understand: How to assess the functional ability of the older adult Why a focus on function is important How to perform a comprehensive geriatric assessment
**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
A 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054)
A 5-HT 6 antagonist in advanced development for the treatment of mild and moderate Alzheimer s disease: idalopirdine (Lu AE58054) producti Congrès National des unités de soins, d'évaluation et de prise
Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review
An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease
ORIGINAL RESEARCH An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease Charlene R. Hoffman Snyder, DNP, FNP-BC, and Lynda Facchiano, DNP,
Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE
Memantine (Namenda ) [Developed, April 2010; Revised, March 2012; March 2014] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or diagnosis is assumed to be unavailable.
Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi.
Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi. Suresh Kumar, M.D. AUTHOR Director of: Neurology & Headaches Center Inc. Neurocognitve &TBI Rehabilitation Center
Dementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa
Dementia Your medicine Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats
N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY)
Bro Taf Localities Drugs & Therapeutics Committee SHARED CARE Drugs: Acetylcholinesterase inhibitors - Donepezil, Rivastigmine and Galantamine (Cardiff and Vale and Cwm Taf) Protocol No. CV 52 N-methyl-D-aspartate
P/OTD 541 Critical Analysis of Occupational Therapy Practice OTD 601 Capstone CRITICALLY APPRAISED TOPIC (CAT) WORKSHEET
Occupational Therapy Department Creighton University P/OTD 541 Critical Analysis of Occupational Therapy Practice OTD 601 Capstone CRITICALLY APPRAISED TOPIC (CAT) WORKSHEET Focused Question: What is the
Dementia Causes and Neuropsychological Evaluation of the Older Adult
Dementia Causes and Neuropsychological Evaluation of the Older Adult Laurie N. Culp, Ph.D. Pate and Culp Psychological Assoc. 2440 Lawrenceville Highway Suite 200 Decatur, GA 30033 678-595-0062 [email protected]
FINANCIAL CAPACITY IN THE ELDERLY. Linda Ganzini, MD, MPH Neisha D Souza, MD
FINANCIAL CAPACITY IN THE ELDERLY Linda Ganzini, MD, MPH Neisha D Souza, MD Overview Mild cognitive impairment (MCI, minor neurocognitive disorder) and dementia (major neurocognitive disorder) Financial
IJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN 2319-2003 Online ISSN 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20150415 Research Article A prospective open-label randomized comparative
How To Write Long Term Care Insurance
By Lori Boyce, AVP Risk Management and R&D Underwriting long term care insurance: a primer Every day Canadians die, are diagnosed with cancer, have heart attacks and become disabled and our insurance solutions
Prescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
Rehabilitation Integrated Transition Tracking System (RITTS)
Rehab Criteria The patient must have a physical impairment requiring rehabilitation OR have a known cognitive impairment requiring ongoing rehabilitation support or services. The patient is medically stable:
Chemobrain. Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015
Chemobrain Halle C.F. Moore, MD The Cleveland Clinic October 3, 2015 Terminology Chemotherapy-associated cognitive dysfunction Post-chemotherapy cognitive impairment Cancer treatment-associated cognitive
Table 1: Approved Memantine Adult Dosage Recommendations 1-6
About Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information
Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI)
Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI) Mike R. Schoenberg, PhD, ABPP-CN Diplomate, American Board of Clinical Neuropsychology Licensed Psychologist Departments of Psychiatry
UPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED 10-18-13
UPDATES TO NEUROCOGNITIVE DISORDERS IN DSM-5 and DSM-5 DESK REFERENCE UPDATED 10-18-13 SUMMARY: These coding changes ensure that insurance reimbursement can be obtained when the specifier With behavioral
Clinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
Participating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
Dementia Friendly Health Care Setting
Dementia Friendly Health Care Setting Health care professionals play a key supportive role for people with dementia and their care partners. They can promote early diagnosis and provide ongoing medical
Assessment of Cognition in Depression Treatment Studies. Philip D. Harvey, PhD University of Miami Miller School of Medicine
Assessment of Cognition in Depression Treatment Studies Philip D. Harvey, PhD University of Miami Miller School of Medicine Disclosures In the past 12 months Dr. Harvey has served as a consultant for:
Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.
Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Memory loss and changes in mood and behavior are some signs that you or a family member may have Alzheimer s disease. If you have
The Senior Care Continuum: A quick guide to the options
The Senior Care Continuum: A quick guide to the options As they begin their searches, families may be overwhelmed by the sheer number of in-home care and senior housing choices. For some, the result is
